This Article Full Text Full Text (PDF) All Versions of this Article: 39/4/1109    most recent STROKEAHA.107.491969v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Google Scholar Articles by Bevan, S. Articles by Markus, H. S. PubMed PubMed Citation Articles by Bevan, S. Articles by Markus, H. S. Pubmed/NCBI databases Gene GEO Profiles HomoloGene Nucleotide Protein UniGene Medline Plus Health Information Stroke Related Collections Genetics of cardiovascular disease Embolic stroke Genetics of Stroke Related Article

(Stroke. 2008;39:1109.)
© 2008 American Heart Association, Inc.

Original Contributions

Genetic Variation in Members of the Leukotriene Biosynthesis Pathway Confer an Increased Risk of Ischemic Stroke

A Replication Study in Two Independent Populations

Steve Bevan, BSc, PhD; Martin Dichgans, MD; H. Erich Wiechmann, PhD; Andreas Gschwendtner, MD; Thomas Meitinger, PhD Hugh S. Markus, DM, FRCP

From Centre for Clinical Neuroscience (S.B., H.S.M.), St. Georges, University of London, UK; Neurologische Klinik (M.D., A.G.), Ludwig-Maximilians-University, Munich, Germany; Institute of Human Genetics (H.E.W., T.M.), GSF—National Research Institute for Environment and Health, Neuherberg, Germany.

Correspondence to Dr Steve Bevan, Centre for Clinical Neuroscience, St Georges University of London, Cranmer Terrace, Tooting, London, SW17 0RE, UK. E-mail sbevan{at}sgul.ac.uk

Background and Purpose— The recent finding that genetic variants in 5-lipoxygenase activating protein and leukotriene A4 hydrolase may confer an increased risk of ischemic stroke has implicated the leukotriene family as potential mediators of cardiovascular disease. Using a case control replication methodology, all members of the leukotriene synthesis pathway and their receptors were examined for genetic variants, which may act as risk factors for all ischemic stroke and stroke subtypes.

Methods— A case control methodology using a UK stroke cohort (872 cases, 933 controls) was adopted, with additional 5-lipoxygenase activating protein genotyping and replication of positive findings undertaken in an independent stroke population from Germany (601 cases, 736 controls).

Results— Association was identified with variants in 5-lipoxygenase activating protein, leukotriene C4 synthase (leukotriene A4 hydrolase),and the leukotriene B4 receptor complex. Differing risks were identified for ischemic stroke subtypes. A variant in leukotriene C4 synthase was found to confer a 1.5-fold increase in risk of small vessel disease (RR, 1.515; 1.041 to 2.262; P=0.043) with replication in an independent cohort showing a similar risk (RR, 1.687; 1.065 to 2.675; P=0.026). A haplotype in the leukotriene B4 receptor complex was found to confer a 2.3-fold increase in risk of cardioembolic stroke (RR, 2.118; 1.194 to 3.760; P=0.01) and replication in a German cohort revealed a similar risk with a second distinct haplotype (RR, 2.060; 1.162 to 3.665; P=0.013).

Conclusions— Genetic variation in leukotriene pathway members and their receptors confer an increased risk of ischemic stroke in 2 independent populations. These risks show different magnitudes depending on ischemic stroke subtype.

Key Words: genetics • inflammation • stroke

Related Article:

Where Do We Go for Atherothrombotic Disease Genetics?

Stefan-Martin Brand-Herrmann
Stroke 2008 39: 1070-1075. [Full Text] [PDF]

This article has been cited by other articles:

				S.-M. Brand-Herrmann Where Do We Go for Atherothrombotic Disease Genetics? Stroke, April 1, 2008; 39(4): 1070 - 1075. [Full Text] [PDF]